Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA Piloting Oncology Supplement Review Using Only Data Summaries

This article was originally published in The Pink Sheet Daily

Executive Summary

Advantages could be shorter review times and expanded labels, but there are concerns about no global regulator having access to full patient-level data.

You may also be interested in...

Generics REMS Hurdles Lowered Somewhat By FDA Protocol Letters

But the U.S. FDA still cannot force brand firms to provide products for bioequivalence testing, which may limit the policy’s ability to remove a barrier that generic firms allege some NDA sponsors use to block competition.

Avastin Ovarian Cancer Approval Brings Some Clarity On PFS Endpoint

New claim for platinum-resistant recurrent disease based on a median 3.4-month improvement in progression-free survival – with favorable trends in overall survival, overall response rate and duration of response – confirms agency’s willingness to entertain a progression endpoint in this tumor type.

FDA/EU Mutual Reliance For GMP Inspections Moving Forward

Both sides may agree to overlook “areas of divergence” if they don’t appear significant.

Related Content


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts